JP2022530833A5 - - Google Patents

Info

Publication number
JP2022530833A5
JP2022530833A5 JP2021565001A JP2021565001A JP2022530833A5 JP 2022530833 A5 JP2022530833 A5 JP 2022530833A5 JP 2021565001 A JP2021565001 A JP 2021565001A JP 2021565001 A JP2021565001 A JP 2021565001A JP 2022530833 A5 JP2022530833 A5 JP 2022530833A5
Authority
JP
Japan
Prior art keywords
sequence
raav
expression cassette
optionally
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021565001A
Other languages
English (en)
Japanese (ja)
Other versions
JP7585233B2 (ja
JP2022530833A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/030484 external-priority patent/WO2020223356A1/en
Publication of JP2022530833A publication Critical patent/JP2022530833A/ja
Publication of JP2022530833A5 publication Critical patent/JP2022530833A5/ja
Application granted granted Critical
Publication of JP7585233B2 publication Critical patent/JP7585233B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021565001A 2019-04-30 2020-04-29 ポンペ病の治療のために有用な組成物 Active JP7585233B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962840911P 2019-04-30 2019-04-30
US62/840,911 2019-04-30
US201962913401P 2019-10-10 2019-10-10
US62/913,401 2019-10-10
PCT/US2020/030484 WO2020223356A1 (en) 2019-04-30 2020-04-29 Compositions useful for treatment of pompe disease

Publications (3)

Publication Number Publication Date
JP2022530833A JP2022530833A (ja) 2022-07-01
JP2022530833A5 true JP2022530833A5 (enExample) 2023-05-08
JP7585233B2 JP7585233B2 (ja) 2024-11-18

Family

ID=73029176

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021565001A Active JP7585233B2 (ja) 2019-04-30 2020-04-29 ポンペ病の治療のために有用な組成物
JP2021564730A Pending JP2022530824A (ja) 2019-04-30 2020-04-29 ポンペ病の治療のために有用な組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021564730A Pending JP2022530824A (ja) 2019-04-30 2020-04-29 ポンペ病の治療のために有用な組成物

Country Status (16)

Country Link
US (2) US20220193207A1 (enExample)
EP (2) EP3963063A4 (enExample)
JP (2) JP7585233B2 (enExample)
KR (2) KR20220008280A (enExample)
CN (2) CN114072515A (enExample)
AU (2) AU2020266829A1 (enExample)
BR (2) BR112021021720A2 (enExample)
CA (2) CA3134485A1 (enExample)
CL (2) CL2021002755A1 (enExample)
CO (2) CO2021016200A2 (enExample)
IL (2) IL287522A (enExample)
MX (2) MX2021013364A (enExample)
PH (2) PH12021552637A1 (enExample)
SG (2) SG11202111380VA (enExample)
TW (1) TW202100541A (enExample)
WO (2) WO2020223356A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3635009T3 (da) 2017-06-07 2026-03-30 Regeneron Pharma Sammensætninger og fremgangsmåder til internalisering af enzymer
US12258597B2 (en) 2018-02-07 2025-03-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
BR112020023145A2 (pt) 2018-05-17 2021-02-02 Regeneron Pharmaceuticals, Inc. anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
KR20220077921A (ko) * 2019-10-10 2022-06-09 아미쿠스 세라퓨틱스, 인코포레이티드 변이체 igf2 작제물
WO2021231863A1 (en) * 2020-05-14 2021-11-18 The Trustees Of The University Of Pennsylvania Compositions useful for treatment of pompe disease
AU2021292200A1 (en) 2020-06-17 2023-02-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of gene therapy patients
KR20240133693A (ko) * 2021-11-12 2024-09-04 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 점액다당류증 iiia의 치료를 위한 유전자 요법
NL2031676B1 (en) * 2022-04-22 2023-11-07 Univ Erasmus Med Ct Rotterdam Gene therapy for Pompe Disease
WO2024003687A1 (en) * 2022-06-28 2024-01-04 Pfizer Inc. Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
WO2024151982A1 (en) * 2023-01-13 2024-07-18 Amicus Therapeutics, Inc. Gene therapy constructs for the treatment of pompe disease
CN116693633B (zh) * 2023-02-21 2023-12-22 广州派真生物技术有限公司 腺相关病毒突变体及其应用
WO2025171163A1 (en) * 2024-02-06 2025-08-14 Duke University Compositions for and methods of treating lysosomal storage diseases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2371913T3 (es) * 2003-01-22 2012-01-11 Duke University Constructos mejorados para expresar polipéptidos lisosomales.
CA2553955C (en) * 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
EP2099523A2 (en) * 2006-11-13 2009-09-16 ZyStor Therapeutics , Inc. Methods for treating pompe disease
EP2623599B1 (en) * 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Micromirs
JP5627571B2 (ja) * 2008-05-07 2014-11-19 バイオマリン ファーマシューティカル インコーポレイテッド リソソーム標的化ペプチドおよびその使用
WO2010096369A1 (en) * 2009-02-18 2010-08-26 Amicus Therapeutics, Inc. Mouse model for pompe disease and methods of use thereof
EP2401406A4 (en) * 2009-02-25 2012-09-19 Cepheid METHODS OF DETECTING LUNG CANCER
EP3679942A1 (en) * 2009-06-17 2020-07-15 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
ES2829199T3 (es) * 2010-11-22 2021-05-31 Amicus Therapeutics Inc Nuevas secuencias de señalización para mejorar la expresión y segregación de proteínas de enzimas recombinantes y otras proteínas
WO2012070014A2 (en) * 2010-11-26 2012-05-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Identification of novel cell surface markers for pancreatic progenitor cells and definite endodermal cells
GB201103062D0 (en) * 2011-02-22 2011-04-06 Isis Innovation Method
HRP20180291T1 (hr) * 2011-05-27 2018-03-23 Amicus Therapeutics, Inc. Postupci za sparivanje ciljajućeg peptida na rekombinantne lizosomalne enzime za poboljšano liječenje lizosomskih bolesti nakupljanja
WO2013013019A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Lysosomal polypeptides, methods of making and using
US20170037431A1 (en) * 2014-05-01 2017-02-09 University Of Washington In vivo Gene Engineering with Adenoviral Vectors
KR102423442B1 (ko) * 2015-12-11 2022-07-20 캘리포니아 인스티튜트 오브 테크놀로지 아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드
AU2017239641A1 (en) * 2016-03-30 2018-10-18 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
EP3293260A1 (en) * 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
WO2018046774A1 (en) * 2016-09-12 2018-03-15 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293259A1 (en) * 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
WO2018178067A1 (en) * 2017-03-27 2018-10-04 Vrije Universiteit Brussel Diaphragm-specific nucleic acid regulatory elements and methods and use thereof
JP2018198611A (ja) * 2018-08-03 2018-12-20 ウニベルシダッド アウトノマ デ バルセロナ 脂肪組織に形質導入するのに有用なアデノ随伴ウイルスベクター

Similar Documents

Publication Publication Date Title
JP2022530833A5 (enExample)
JP2022530824A5 (enExample)
JP7707261B2 (ja) 筋疾患の治療のための改変ａａｖカプシドポリペプチド
US20220169701A1 (en) Enveloped Virus Resistant to Complement Inactivation for the Treatment of Cancer
TW202102526A (zh) 重組腺相關病毒及其用途
JP2022531861A5 (enExample)
JP2021512649A (ja) 転写調節要素及びその使用
CA3121528A1 (en) Anellosomes and methods of use
CN113166777B (zh) 含有AIMP2-DX2和miR-142的靶核酸的载体及其用途
US20240002462A1 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
JP2022553406A5 (enExample)
JP2021508241A5 (enExample)
KR102267837B1 (ko) 재조합 백시니아 바이러스 및 이를 포함하는 약학 조성물
EP0596969A1 (en) Igf-ii analogues
EP4509606A1 (en) Nucleic acid construct for treating hereditary coagulation factor deficiency and use thereof
WO1999061034A1 (en) Improved vectors
KR101756131B1 (ko) 간세포 성장인자 및 기질세포 유발인자1알파를 이용한 말초동맥질환의 예방 또는 치료용 조성물
US20170065685A1 (en) Serca2 therapeutic compositions and methods of use
KR20220154106A (ko) 타우병증 치료를 위한 mirna-485 억제제의 용도
KR20220027829A (ko) 심장보호 활성 갖는 단백질
US20240335506A1 (en) Aqp1 gene therapy to prevent radiation induced salivary hypofunction
KR20220154105A (ko) 근위축성 측삭 경화증(als) 치료를 위한 mirna-485 억제제의 용도
WO1998043665A1 (fr) Agent preventif et/ou therapeutique pour les maladies des reins
WO2024216244A2 (en) Targeting aav capsids, methods of manufacturing and using same
KR20250167670A (ko) 초극소 역위 말단 반복(itr) 서열 및 그의 용도